Mark Albers is a Neurology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
15 Parkman Street
Wacc 830
Boston, MA 02114
Telephone
617-726-1728Registry record last updated 17 Aug 2009.
Clinical trials
- Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD
Sponsor: Massachusetts General Hospital
- Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
Sponsor: Massachusetts General Hospital
- Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
Sponsor: Massachusetts General Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202415 payments$15,186openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Cholinesterase Inhibitor64.6%Galantamine Er59%Rivastigmine30%Galantamine Hbr7%Donepezil Hcl5%Part D<11 patientsN-methyl-D-aspartate Receptor Antagonist19.7%Memantine Hcl85%Memantine Hcl Er15%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
9 NIH research awards on record, funded 2009–2026 per NIH RePORTER. The latest:
- Defining the pathogenic relationship of TDP-43 inclusions and cytoplasmic double stranded RNA in AD and FTD
Harvard Medical School
FY2026$821,162R01AG078377 - Harnessing Diverse Bioinformatic Approaches To Repurpose Drugs For Alzheimers Disease And Related Dementias
Massachusetts General Hospital
FY2026$759,915R01AG058063 - Harnessing Diverse Bioinformatic Approaches To Repurpose Drugs For Alzheimers Disease And Related Dementias
Massachusetts General Hospital
FY2026$115,560R01AG058063
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”